Axa Equitable Holdings Inc is an insurance-diversified business based in the US. Axa Equitable shares (EQH) are listed on the NYSE and all prices are listed in US Dollars. Axa Equitable employs 12,100 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $26.32 |
|---|---|
| 52-week range | $25.22 - $36.67 |
| 50-day moving average | $28.36 |
| 200-day moving average | $31.45 |
| Wall St. target price | $42.00 |
| PE ratio | 7.211 |
| Dividend yield | $0.55 (3.04%) |
| Earnings per share (TTM) | $3.65 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $26.32 from 2022-07-01
| 1 week (2022-06-28) | -2.55% |
|---|---|
| 1 month (2022-06-06) | -11.35% |
| 3 months (2022-04-06) | -16.55% |
| 6 months (2022-01-06) | -25.06% |
| 1 year (2021-07-06) | -11.08% |
|---|---|
| 2 years (2020-07-06) | 35.53% |
| 3 years (2019-07-05) | 20.57% |
| 5 years (2017-07-02) | N/A |
Valuing Axa Equitable stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Axa Equitable's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Axa Equitable's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Axa Equitable shares trade at around 7x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Axa Equitable's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.4 billion.
The EBITDA is a measure of a Axa Equitable's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $16.1 billion |
|---|---|
| Operating margin TTM | 30.72% |
| Gross profit TTM | $4.5 billion |
| Return on assets TTM | 1.12% |
| Return on equity TTM | 18.09% |
| Profit margin | 10.05% |
| Book value | $16.63 |
| Market capitalisation | $10 billion |
TTM: trailing 12 months
Dividend payout ratio: 11.3% of net profits
Recently Axa Equitable has paid out, on average, around 11.3% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.04% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Axa Equitable shareholders could enjoy a 3.04% return on their shares, in the form of dividend payments. In Axa Equitable's case, that would currently equate to about $0.55 per share.
While Axa Equitable's payout ratio might seem low, this can signify that Axa Equitable is investing more in its future growth.
Axa Equitable's most recent dividend payout was on 5 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 25 May 2022 (the "ex-dividend date").
Over the last 12 months, Axa Equitable's shares have ranged in value from as little as $25.22 up to $36.6696. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Axa Equitable's is 1.4864. This would suggest that Axa Equitable's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Equitable Holdings, Inc. , together with its consolidated subsidiaries, operates as a diversified financial services company worldwide. The company operates through four segments: Individual Retirement, Group Retirement, Investment Management and Research, and Protection Solutions. The Individual Retirement segment offers a suite of variable annuity products primarily to affluent and high net worth individuals. The Group Retirement segment provides tax-deferred investment and retirement services or products to plans sponsored by educational entities, municipalities, and not-for-profit entities, as well as small and medium-sized businesses. The Investment Management and Research segment offers diversified investment management, research, and related solutions to various clients through institutional, retail, and private wealth management channels; and distributes its institutional research products and solutions. The Protection Solutions segment provides various variable universal life, indexed universal life, and term life products to help affluent and high net worth individuals, as well as small and medium-sized business owners; and a suite of life, short- and long-term disability, dental, and vision insurance products to small and medium-size businesses.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.